2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P990167
    Anti-Mouse/Human PrP/prion protein Antibody (TW1) 98%
    Anti-Mouse/Human PrP/prion protein Antibody (TW1) is a mouse-derived IgG2a type antibody inhibitor, targeting to mouse/human PrP/prion protein. Anti-Mouse/Human PrP/prion protein Antibody (TW1) binds to both PrPc (cellular prion protein) and PrPSc (Scrapie Prion Protein) and blocks the interaction of prion protein with tau protein. Anti-Mouse/Human PrP/prion protein Antibody (TW1) can be used for the researches of Alzheimer’s disease (AD).
    Anti-Mouse/Human PrP/prion protein Antibody (TW1)
  • HY-P990229
    Anti-Rat IgG2b Antibody (RG7/11.1)
    Anti-Rat IgG2b Antibody (RG7/11.1) is an anti-rat IgG2b monoclonal antibody. Anti-Rat IgG2b Antibody (RG7/11.1) can be used for research on neurological and infection conditions such as temporal lobe epilepsy (TLE). Anti-Rat IgG2b Antibody (RG7/11.1) is often used for the same type control.
    Anti-Rat IgG2b Antibody (RG7/11.1)
  • HY-P990248
    Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) 98%
    Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) is an anti-mouse E-Cadherin/CD324 IgG1 monoclonal antibody. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can downregulate the HER signaling axis and PI3K/Akt/mTOR signaling pathway. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can inhibit the proliferation of tumor cells and induce their apoptosis. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can be used for researches on cancer and inflammation conditions such as breast cancer, chronic compression injury (CCI) and asthma.
    Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1)
  • HY-P991073
    MEDI-1814 98%
    MEDI-1814 is a fully human IgG1 antibody that targets the C terminus of Aβ42. MEDI-1814 binds to and sweeps away the circulated Aβ peptides, hence, restricting them from aggregating into toxic oligomers. MEDI-1814 can be used for the study of Alzheimer's diseases. The isotype control for MEDI-1814 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    MEDI-1814
  • HY-P991098
    Anti-TrkB/NTRK2 Antibody 98%
    Anti-TrkB/NTRK2 Antibody is a human antibody expressed in CHO cells, targeting TrkB. Anti-TrkB/NTRK2 Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
    Anti-TrkB/NTRK2 Antibody
  • HY-P991101
    Anti-Amyloid Beta Antibody (scFv59) 98%
    Anti-Amyloid Beta Antibody (scFv59) is a human antibody expressed in CHO cells, targeting Amyloid-β. Anti-Amyloid Beta Antibody (scFv59) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-Amyloid Beta Antibody (scFv59)
  • HY-P991158
    Rinvatercept 2996105-98-5 98%
    Rinvatercept, a fusion protein, is a glycyl (1)-chimeric N-terminal (1-108)-peptide (2-109) combined from the sequences of the extracellular domains of the human ACVR2A/B, and is fused via a G3 peptide linker (110-112) to an immunoglobulin G1 (IgG1) Fc fragment. Rinvatercept can be used for research of neuromuscular disease.
    Rinvatercept
  • HY-P991168
    Velaprumig 2988741-17-7 98%
    Velaprumig is a monoclonal antibody targeting human CD99, CCL25, and anti-human Aβ (Aβ-47F). Velaprumig regulates immune cell migration and reduces β-amyloid-related pathological processes, exerting immunomodulatory and potential anti - Alzheimer's disease activities.
    Velaprumig
  • HY-P991310
    Lpathomab 1253114-37-2 98%
    Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
    Lpathomab
  • HY-P991376
    BIIB076 98%
    BIIB076 is a human monoclonal antibody (mAb) targeting PHF-tau. BIIB076 can be used for passive immunity research in Alzheimer's disease (AD).
    BIIB076
  • HY-P991377
    TBL-100 98%
    TBL-100 is a human monoclonal antibody (mAb) targeting Tau. TBL-100 can be used in Alzheimer's disease (AD) and Progressive supranuclear palsy research.
    TBL-100
  • HY-P991380
    TXB4 98%
    TXB4 is a brain-permeable human monoclonal antibody (mAb) targeting CD71. TXB4 prevents 6-OHDA-induced death of TH-positive neurons in the SNc in a 6-OHDA mouse model of Parkinson's disease (PD). TXB4 can be used in neurodegenerative diseases, acute brain and spinal cord injury, and depression research.
    TXB4
  • HY-P991385
    UBX2050 98%
    UBX2050 is a human monoclonal antibody (mAb) targeting TIE2. UBX2050 can be used in Age-related macular degeneration, Diabetic macular oedema and Diabetic retinopathy research.
    UBX2050
  • HY-P991412
    NI-301 98%
    NI-301 is a human monoclonal antibody (mAb) targeting Transthyretin/TTR. NI-301 can be used in Cardiomyopathies and Familial amyloid neuropathy research.
    NI-301
  • HY-P991435
    CEP-37248 98%
    CEP-37248 is a human monoclonal antibody (mAb) targeting IL-12. CEP-37248 can be used in Alzheimer's disease research.
    CEP-37248
  • HY-P991478
    RLVT-14-02 98%
    RLVT-14-02 is a human monoclonal antibody (mAb) targeting MMP14. RLVT-14-02 can be used in neuropathic pain research.
    RLVT-14-02
  • HY-P991534
    PF-04382923 98%
    PF-04382923 is a humanized IgG2Δa monoclonal antibody. PF-04382923 binds with high affinity to the free C-terminal regions of the amyloid-β peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD).
    PF-04382923
  • HY-P991535
    PMN310 98%
    PMN310 is a monoclonal antibody targeting amyloid-β oligomers (AβO). PMN310 prevents AβO-induced memory loss and reduces synaptic loss and inflammation in vivo. PMN310 is potentially useful in Alzheimer's disease research.
    PMN310
  • HY-P991536
    KHK6640 98%
    KHK6640 is a humanized anti-amyloid beta oligomer-specific antibody. KHK6640 demonstrates high potency and efficacy for cognitive improvement in several rodent Alzheimer’s models. KHK6640 can be studied in research for neurological diseases such as Alzheimer’s disease.
    KHK6640
  • HY-P991654
    SAR228810 98%
    SAR228810 is a humanized IgG4 monoclonal antibody inhibitor targeting amyloid β (Aβ) with a KD? of ?0.43 ?nM for protofibrillar Aβ over monomeric Aβ. SAR228810 significantly inhibits the brain amyloid plaque formation and oligomer-induced synaptic dysfunction and neurite loss. SAR228810 has significant protection against Aβ-mediated neuritotoxicity. MINT1526A can be used for Alzheimer’s disease imaging and immunotherapy research.
    SAR228810
Cat. No. Product Name / Synonyms Application Reactivity